Top Biotech Companies To Invest In 2015

Top Biotech Companies To Invest In 2015: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Garrett Cook]

  Vertex Pharmaceuticals (NASDAQ: VRTX) shares shot up 41.12 percent to $94.00 after the company reported that its two phase 3 studies of Lumacaftor in combination with ivacaftor met the primary endpoint.

• [By Garrett Cook]

  Vertex Pharmaceuticals (NASDAQ: VRTX) shares shot up 42.73 percent to $95.07 after the company reported that its two phase 3 studies of Lumacaftor in ! combination with ivacaftor met the primary endpoint.

• [By Ben Rooney]

  You might not have heard of Vertex Pharmaceuticals (VRTX), but it's worth looking up today. Shares soared 40% after the company said a study of its cystic fibrosis drug produced positive results.

• [By Ben Levisohn]

  Vertex Pharmaceuticals (VRTX) popped 9.2% to $71.04 this week. The Street.com’s Adam Feuerstein predicted the Vertex’s cystic fibrosis drug would be successful in clinical trials.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-biotech-companies-to-invest-in-2015.html